Neurocrine Biosciences Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B

Benzinga · 1d ago

Neurocrine Biosciences (NASDAQ:NBIX) Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B